Interpretation of Changes in Circulating Tumor Cell Counts

Overview

Journal Transl Oncol

Specialty Oncology

Date 2013 Jan 17

PMID 23323160

Citations 23

Authors

Frank Aw Coumans

Sjoerd T Ligthart

Leon Wmm Terstappen

Affiliations

Soon will be listed here.

Abstract

The presence of circulating tumor cells (CTCs) in the blood of cancer patients may guide the use of therapy. We investigated how to evaluate a reduction in the number of CTCs after administration of therapy. CTCs were enumerated with the CellSearch system in 111 metastatic breast and 185 metastatic prostate cancer patients before start of a new line of chemotherapy and after initiation of therapy. Different means to express changes in CTC counts were evaluated with respect to overall survival (OS). A static CTC cutoff is the best method to determine whether a therapy is effective. This is exemplified by the highest Cox hazard ratio of 2.1 for OS; three methods to express relative differences performed worse. A lookup table is provided from which the significance of a change in CTCs can be derived. The aim of therapy should be the elimination of all CTCs. A period of 10 to 12 weeks of therapy is needed to reach the treatment effect on CTCs.

Citing Articles

Clinical Significance of Circulating Tumor Cells in Patients with Esophageal Cancer.

Kitano H, Nasu M, Hashimoto T, Tsurumaru M, Kajiyama Y Juntendo Iji Zasshi. 2024; 68(4):369-374.

PMID: 39021432 PMC: 11249976. DOI: 10.14789/jmj.JMJ21-0049-OA.

Signatures of Breast Cancer Progression in the Blood: What Could Be Learned from Circulating Tumor Cell Transcriptomes.

Fina E Cancers (Basel). 2022; 14(22).

PMID: 36428760 PMC: 9688726. DOI: 10.3390/cancers14225668.

Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma.

Chiang P, Xu T, Cha T, Tsai Y, Liu S, Wu S Biology (Basel). 2021; 10(7).

PMID: 34356529 PMC: 8301435. DOI: 10.3390/biology10070674.

Future perspectives from lung cancer pre-clinical models: new treatments are coming?.

Bersani F, Morena D, Picca F, Morotti A, Tabbo F, Bironzo P Transl Lung Cancer Res. 2021; 9(6):2629-2644.

PMID: 33489823 PMC: 7815341. DOI: 10.21037/tlcr-20-189.

Short-Term Circulating Tumor Cell Dynamics in Mouse Xenograft Models and Implications for Liquid Biopsy.

Williams A, Fitzgerald J, Ivich F, Sontag E, Niedre M Front Oncol. 2020; 10:601085.

PMID: 33240820 PMC: 7677561. DOI: 10.3389/fonc.2020.601085.

References

Budd G, Cristofanilli M, Ellis M, Stopeck A, Borden E, Miller M . Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006; 12(21):6403-9. DOI: 10.1158/1078-0432.CCR-05-1769. View

Shaffer D, Leversha M, Danila D, Lin O, Gonzalez-Espinoza R, Gu B . Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res. 2007; 13(7):2023-9. DOI: 10.1158/1078-0432.CCR-06-2701. View

De Giorgi U, Valero V, Rohren E, Mego M, Doyle G, Miller M . Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol. 2009; 21(1):33-9. DOI: 10.1093/annonc/mdp262. View

Allard W, Matera J, Miller M, Repollet M, Connelly M, Rao C . Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20):6897-904. DOI: 10.1158/1078-0432.CCR-04-0378. View

Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B . Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007; 13(3):920-8. DOI: 10.1158/1078-0432.CCR-06-1695. View

Bidard F, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P . Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol. 2009; 21(4):729-733. DOI: 10.1093/annonc/mdp391. View

Hayes D, Cristofanilli M, Budd G, Ellis M, Stopeck A, Miller M . Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006; 12(14 Pt 1):4218-24. DOI: 10.1158/1078-0432.CCR-05-2821. View

Rao C, Bui T, Connelly M, Doyle G, Karydis I, Middleton M . Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol. 2011; 38(3):755-60. DOI: 10.3892/ijo.2011.896. View

Krebs M, Sloane R, Priest L, Lancashire L, Hou J, Greystoke A . Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011; 29(12):1556-63. DOI: 10.1200/JCO.2010.28.7045. View

10.

Matsusaka S, Chin K, Ogura M, Suenaga M, Shinozaki E, Mishima Y . Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer Sci. 2010; 101(4):1067-71. PMC: 11159155. DOI: 10.1111/j.1349-7006.2010.01492.x. View

11.

Yagata H, Nakamura S, Toi M, Bando H, Ohno S, Kataoka A . Evaluation of circulating tumor cells in patients with breast cancer: multi-institutional clinical trial in Japan. Int J Clin Oncol. 2008; 13(3):252-6. DOI: 10.1007/s10147-007-0748-9. View

12.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

13.

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

14.

Tibbe A, Miller M, Terstappen L . Statistical considerations for enumeration of circulating tumor cells. Cytometry A. 2007; 71(3):154-62. DOI: 10.1002/cyto.a.20369. View

15.

Scher H, Jia X, de Bono J, Fleisher M, Pienta K, Raghavan D . Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009; 10(3):233-9. PMC: 2774131. DOI: 10.1016/S1470-2045(08)70340-1. View

16.

Liu M, Shields P, Warren R, Cohen P, Wilkinson M, Ottaviano Y . Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol. 2009; 27(31):5153-9. PMC: 4879719. DOI: 10.1200/JCO.2008.20.6664. View

17.

Krebs M, Hou J, Sloane R, Lancashire L, Priest L, Nonaka D . Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol. 2011; 7(2):306-15. DOI: 10.1097/JTO.0b013e31823c5c16. View

18.

Coumans F, Ligthart S, Uhr J, Terstappen L . Challenges in the enumeration and phenotyping of CTC. Clin Cancer Res. 2012; 18(20):5711-8. DOI: 10.1158/1078-0432.CCR-12-1585. View

19.

Hiltermann T, Pore M, van den Berg A, Timens W, Boezen H, Liesker J . Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol. 2012; 23(11):2937-2942. DOI: 10.1093/annonc/mds138. View

20.

Cohen S, Punt C, Iannotti N, Saidman B, Sabbath K, Gabrail N . Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(19):3213-21. DOI: 10.1200/JCO.2007.15.8923. View